Zymeworks BC Inc

NASDAQ:ZYME  
13.04
+0.15 (+1.16%)
4:19:47 PM EDT: $13.04 0.00 (0.00%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)926.73M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$16.87 Million
Adjusted EPS-$0.49
See more estimates
10-Day MAN/A
50-Day MAN/A
200-Day MAN/A
See more pivots

Zymeworks BC Inc Stock, NASDAQ:ZYME

108 Patriot Drive, Suite A, Middletown, Delaware 19709
Canada
Phone: +1.302.274.8744
Number of Employees: 286

Description

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.